BR112019024082A2 - Métodos de tratamento para distonia cervical - Google Patents

Métodos de tratamento para distonia cervical Download PDF

Info

Publication number
BR112019024082A2
BR112019024082A2 BR112019024082-9A BR112019024082A BR112019024082A2 BR 112019024082 A2 BR112019024082 A2 BR 112019024082A2 BR 112019024082 A BR112019024082 A BR 112019024082A BR 112019024082 A2 BR112019024082 A2 BR 112019024082A2
Authority
BR
Brazil
Prior art keywords
compositions
cervical dystonia
treatment methods
effect
injectable
Prior art date
Application number
BR112019024082-9A
Other languages
English (en)
Portuguese (pt)
Inventor
L. Ruegg Curtis
M. Waugh Jacob
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of BR112019024082A2 publication Critical patent/BR112019024082A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112019024082-9A 2017-05-18 2018-05-18 Métodos de tratamento para distonia cervical BR112019024082A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508324P 2017-05-18 2017-05-18
US62/508,324 2017-05-18
PCT/US2018/033397 WO2018213710A1 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia

Publications (1)

Publication Number Publication Date
BR112019024082A2 true BR112019024082A2 (pt) 2020-06-16

Family

ID=64274745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024082-9A BR112019024082A2 (pt) 2017-05-18 2018-05-18 Métodos de tratamento para distonia cervical

Country Status (13)

Country Link
US (3) US20200179498A1 (https=)
EP (1) EP3624819A4 (https=)
JP (1) JP2020520917A (https=)
KR (2) KR102777928B1 (https=)
CN (1) CN110996979A (https=)
AU (2) AU2018270092C1 (https=)
BR (1) BR112019024082A2 (https=)
CA (1) CA3064070A1 (https=)
CO (1) CO2019014212A2 (https=)
MX (1) MX2019013716A (https=)
PH (1) PH12019502578A1 (https=)
RU (1) RU2019141383A (https=)
WO (1) WO2018213710A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20230086752A (ko) * 2020-10-13 2023-06-15 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
US20250268996A1 (en) * 2021-02-21 2025-08-28 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
AU2024342863A1 (en) 2023-09-15 2026-04-09 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
AU2009332947C1 (en) * 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) * 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US8147848B2 (en) * 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
PT2661276T (pt) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
SG11202005239YA (en) 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
RU2741221C1 (ru) 2020-04-30 2021-01-22 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом

Also Published As

Publication number Publication date
US20200179498A1 (en) 2020-06-11
RU2019141383A3 (https=) 2022-01-19
KR20200006587A (ko) 2020-01-20
CO2019014212A2 (es) 2020-01-17
MX2019013716A (es) 2020-10-12
US12257293B2 (en) 2025-03-25
NZ759612A (en) 2024-01-26
EP3624819A4 (en) 2021-03-24
AU2025205532A1 (en) 2025-08-07
AU2018270092B2 (en) 2025-04-17
PH12019502578A1 (en) 2020-07-20
JP2020520917A (ja) 2020-07-16
US20220096610A1 (en) 2022-03-31
KR102777928B1 (ko) 2025-03-10
EP3624819A1 (en) 2020-03-25
AU2018270092A1 (en) 2019-12-19
KR20250037595A (ko) 2025-03-17
US20250319168A1 (en) 2025-10-16
CA3064070A1 (en) 2018-11-22
WO2018213710A1 (en) 2018-11-22
CN110996979A (zh) 2020-04-10
RU2019141383A (ru) 2021-06-18
AU2018270092C1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
BR112017011536A2 (pt) terapias de combinação
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2020013120A (es) Tratamiento terapéutico de cánceres de microsatélites inestables.
JOP20210050A1 (ar) معدلات تعبير pnpla3
BR112018008965A8 (pt) terapia de reposição de plasminogênio para deficiência de plasminogênio
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112017007813A2 (pt) composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
BR112022006016A2 (pt) Métodos e materiais para tratar neurotoxicidade
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2020006043A (es) Tratamiento de trastornos autonomicos con toxina botulinica.
MX388998B (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2020003554A (es) Moduladores de la expresion de enac.
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
BR112017016596A2 (pt) composição farmacêutica para prevenir ou tratar a leucemia mieloide crônica, e método de prevenção ou tratamento da leucemia mieloide crônica de um sujeito

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]